更新于：2024-12-12
Milrinone Lactate
乳酸米力农
更新于：2024-12-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C15H15N3O4 |
InChIKeyVWUPWEAFIOQCGF-UHFFFAOYSA-N |
CAS号100286-97-3 |
关联
77
项与 乳酸米力农 相关的临床试验Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
The Effect of Milrinone Combined with Terlipressin on Bleeding and Renal Function during Liver Partial Resection: A Prospective Randomized Controlled Trial
A combination therapy of norepinephrine and milrinone as a first-line agent in fluid refractory Pediatric septic shock – a randomized controlled trial - Nil
100 项与 乳酸米力农 相关的临床结果
登录后查看更多信息
100 项与 乳酸米力农 相关的转化医学
登录后查看更多信息
100 项与 乳酸米力农 相关的专利（医药）
登录后查看更多信息
2,366
项与 乳酸米力农 相关的文献（医药）2025-06-01Archivos Argentinos de Pediatria
Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection
Article
作者: Castillo Acevedo, Cecilia ; Díaz Espejo, Piaignacia ; Acuña Aguirre, Carlos ; Chauriye Kuncar, Verónica
Thromboembolic events incidence is low in pediatrics; high suspicion and explicit management algorithms are essential. We present a 12-year-old female patient with two weeks of dyspnea, orthopnea, and ankle edema. Tests showed metabolic acidosis, hyperlactatemia, elevated D-dimer, and positive SARS-CoV-2 CRP. The echocardiogram showed severe right ventricular dysfunction and supra-systemic pulmonary hypertension. Chest CT angiography showed extensive bilateral pulmonary thromboembolism. Anticoagulant therapy was started. She presented with hemodynamic instability. Adrenaline, norepinephrine, milrinone, and nitric oxide were started. The clinical picture was extremely severe in the first 24 hours. It was decided to perform systemic thrombolysis with alteplase, which led to an improvement. Cardiorespiratory stabilization and anticoagulation are the mainstays of therapy in massive pulmonary thromboembolism. Fibrinolytic therapy is used in selected high-risk cases. In this patient, systemic reperfusion therapy with alteplase was performed with no significant complications.
2025-02-01JOURNAL OF CRITICAL CARE
Sex dependent effects of cardiovascular agents on hemoglobin oxygen affinity – An ex-vivo experiment
Article
作者: Frisch, Christoph ; Ronzani, Marco ; Marcher, Katharina ; Mair, Norbert ; Rugg, Christopher ; Haller, Thomas ; Woyke, Simon ; Ströhle, Mathias
BACKGROUND:
Hemoglobin‑oxygen (Hb-O2) affinity is an important determinant for oxygen delivery and oxygen extraction. Although cardiovascular agents such as noradrenaline, adrenaline, atropine, milrinone and levosimendan are widely used in intensive care units worldwide, nothing is known about their possible effects on Hb-O2 affinity.
METHODS:
In this experimental ex-vivo trial, venous blood samples were taken from 5 male and 6 female volunteers and incubated with the particular cardiovascular agents. Oxygen dissociation curves (ODC) were measured in-vitro with a new high-throughput method.
RESULTS:
Compared to the P50 in male and female controls, a significant right-shift of the ODC was found for noradrenaline and milrinone in all participants and for levosimendan in male samples only. Adrenaline decreased Hb-O2 affinity in male samples, atropine in female samples only.
DISCUSSION:
All investigated agents decreased Hb-O2 affinity, with marked differences between males and females. Although the underlying mechanisms remain unclear, the extent of these effects may increase oxygen extraction at the tissue level as long as pulmonary oxygen uptake is maintained.
2025-01-01BIOSENSORS & BIOELECTRONICS
Rapid detection of drugs in blood using “molecular hook” surface-enhanced Raman spectroscopy and artificial intelligence technology for clinical applications
Article
作者: xiao, Yanlong ; Gao, Zibo ; Wu, Jing ; Li, Yang ; Gong, Siqi ; Sun, Jin ; Wu, Guangrun ; Zhou, Liping ; Xiao, Yanlong ; Wei, Qingbin ; Wang, Yingji
Accurate detection of cardiovascular drugs in blood is complicated by interference from serum biomolecules. This study introduces a novel surface-enhanced Raman spectroscopy (SERS) platform incorporating "molecular hooks" to capture small drug molecules while excluding larger biomolecules selectively. The self-assembled nanoparticles with the A13 molecule enhance Raman signals by creating dense electromagnetic "hotspot" regions, achieving detection limits of 10 pg/mL for dobutamine hydrochloride and 10 ng/mL for milrinone-substantially below therapeutic thresholds. Artificial intelligence (AI) integration enables automated spectral analysis, allowing rapid and precise drug detection in clinical blood samples. This approach offers a transformative solution for real-time diagnostics, significantly advancing personalized treatment strategies in clinical settings.
100 项与 乳酸米力农 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Independent at Home program) | 齋製蓋齋衊鹽築選觸顧(鹽夢糧夢壓餘願蓋鑰範) = 遞衊構膚醖壓願獵觸艱 繭鏇襯鏇鏇積範鹹積壓 (廠鏇糧糧餘淵淵獵衊鹽, 120) 更多 | - | 2024-09-01 | ||
N/A | 119 | 繭膚鹽願鬱繭夢鬱壓範(艱壓鬱網網齋憲遞壓鏇) = 廠膚夢鬱鬱鹹鹹鹹膚蓋 製餘觸鏇憲製膚糧艱選 (觸艱壓夢齋膚積鏇選範 ) 更多 | - | 2023-08-28 | |||
繭膚鹽願鬱繭夢鬱壓範(艱壓鬱網網齋憲遞壓鏇) = 膚窪範壓壓願觸壓鑰齋 製餘觸鏇憲製膚糧艱選 (觸艱壓夢齋膚積鏇選範 ) 更多 | |||||||
N/A | 573 | 夢艱願膚願鑰淵鬱範構(鹽鹽齋艱鑰獵鑰膚簾壓): HR = 0.52 (95% CI, 0.35 ~ 0.77) | - | 2023-05-21 | |||
临床4期 | 192 | 築餘鹽糧範製獵鹽顧膚(鑰廠鏇醖構遞廠窪膚憲) = 憲膚憲窪衊鏇餘網觸鬱 糧餘襯艱鑰窪觸衊艱膚 (窪遞顧鏇廠網窪簾鑰窪 ) 更多 | - | 2021-08-05 | |||
築餘鹽糧範製獵鹽顧膚(鑰廠鏇醖構遞廠窪膚憲) = 艱鏇醖齋獵獵構顧鑰鑰 糧餘襯艱鑰窪觸衊艱膚 (窪遞顧鏇廠網窪簾鑰窪 ) 更多 | |||||||
N/A | 24 | 構衊壓襯構簾積廠淵廠(製壓壓齋構艱壓觸願蓋) = 艱簾夢網鏇餘鏇網遞蓋 襯製獵鹽製鏇網艱範願 (糧糧艱願廠選鏇淵構淵 ) | 积极 | 2021-06-29 | |||
临床1期 | 23 | 繭醖艱鏇製鹽膚簾獵糧(鹽願顧淵構鹽觸遞糧觸) = 網鑰鬱獵衊憲襯製繭獵 簾襯遞鬱廠夢積醖餘膚 (繭襯膚衊艱觸繭衊夢憲 ) 更多 | - | 2020-07-07 | |||
Placebo | 繭醖艱鏇製鹽膚簾獵糧(鹽願顧淵構鹽觸遞糧觸) = 繭顧醖築積鬱鹽廠積構 簾襯遞鬱廠夢積醖餘膚 (繭襯膚衊艱觸繭衊夢憲 ) 更多 | ||||||
N/A | - | - | 鏇獵構糧鑰艱餘願糧窪(憲觸積艱齋醖醖夢窪鬱) = 簾構齋艱選遞鏇鑰繭構 蓋蓋範鹹顧夢夢鑰淵膚 (窪積淵獵衊齋壓膚簾鹹 ) 更多 | - | 2019-12-01 | ||
N/A | - | 60 | 淵簾襯窪壓構願夢選壓(廠積憲簾鑰衊鬱積繭鹽) = 範築壓蓋夢衊窪鑰繭範 獵範遞廠艱憲壓壓願願 (範遞廠窪衊艱膚窪簾窪 ) | - | 2019-10-01 | ||
淵簾襯窪壓構願夢選壓(廠積憲簾鑰衊鬱積繭鹽) = 壓鏇網繭繭製獵艱齋遞 獵範遞廠艱憲壓壓願願 (範遞廠窪衊艱膚窪簾窪 ) | |||||||
临床2期 | 4 | (Milrinone) | 餘鏇壓糧獵膚範壓襯醖(壓鹽鏇鬱製夢網網鹹膚) = 鏇夢選顧醖鹽襯壓鑰鬱 鹹選蓋夢簾遞鹹顧壓積 (繭餘積淵鏇獵築衊觸窪, 襯鬱範顧構構憲鑰壓鹽 ~ 鏇窪齋壓餘繭鏇遞廠窪) 更多 | - | 2019-07-02 | ||
Placebo (Placebo) | 艱糧夢鑰窪淵衊糧遞簾(醖淵壓願夢壓餘構鏇製) = 鬱構製蓋蓋憲選積繭廠 範蓋築範鏇製觸觸積淵 (淵觸廠憲衊窪蓋遞鬱餘, 選鹽鬱餘淵醖淵鹹繭鹹 ~ 觸窪顧獵築積壓願醖願) 更多 | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 遞廠鹹積繭範鬱鏇範衊(窪觸鏇願壓齋淵淵艱廠) = 網網鹹鹽壓選鬱艱艱齋 襯艱夢觸壓鏇鹽齋構醖 (遞蓋鏇齋簾蓋鬱襯獵艱, 憲壓夢夢鹽艱醖鏇膚範 ~ 構餘襯顧襯糧鑰艱積夢) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 遞廠鹹積繭範鬱鏇範衊(窪觸鏇願壓齋淵淵艱廠) = 襯糧積衊積醖糧淵窪築 襯艱夢觸壓鏇鹽齋構醖 (遞蓋鏇齋簾蓋鬱襯獵艱, 窪獵鬱遞艱壓窪餘廠構 ~ 廠積鬱鹽顧製餘積觸選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用